PLYMOUTH MEETING, Pa., Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...
"The additional data on INO-3107 presented demonstrate immunogenicity and potential for efficacy," said Dr. Mau. "INO-3107 reduced the need for surgical interventions for most trial participants – ...
Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries PLYMOUTH ...
Inovio (INO) announced data from a retrospective trial showing that the number of Recurrent Respiratory Papillomatosis , or RRP, patients meeting the criteria for a Complete Response, or CR, increased ...
The most widely cited U.S. epidemiology data published in 1995 estimated that there were 14,000 active cases and about 1.8 per 100,000 new cases of RRP in adults each year. About INO-3107 INO-3107 is ...
New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback